Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/11341
|
| Title: | Cardiovascular benefits of acarbose versus sulfonylureas in type 2 diabetic patients treated with metformin |
| Authors: | Hsu, PF;Sung, SH;Cheng, HM;Shin, SJ;Lin, KD;Chong, K;Yen, FS;Yu, BH;Huang, CT;Hsu, CC |
| Contributors: | Institute of Population Health Sciences |
| Abstract: | Context: Althoughalpha-glucosidase inhibitor (AGI) has been shown to reduce the risk of myocardial infarction in patients with impaired glucose tolerance (IGT), the cardiovascular benefits of AGI in type 2 diabetes (T2D) remains unclear. Objective: We aimed to compare clinical outcomes of adding acarbose versus sulfonylureas to metformin therapy in T2D patients. Design, Setting, and Participants: The study population was drawn from the database of the Diabetes Pay-for-Performance (P4P) Program in Taiwan. Sulfonylureas and acarbose were respectively prescribed to 196,143 and 14,306 T2D patients during 2004-2015, who had been treated with metformin. A propensity score-matched cohort study was conducted. Patients were followed for clinical adverse events of all-cause mortality and hospitalizations of major atherosclerotic events (myocardial infarction and ischemic stroke), heart failure or hypoglycemia. Results: A total of 14,306 propensity score-matched pairs (55.8+/-13.1 years, 47.8% men) were enrolled in this analysis. Compared with sulfonylureas as the add-on therapy to metformin, the use of acarbose was associated with significantly lower risks of hospitalizations for major atherosclerotic events (hazard ratio and 95% confidence intervals: 0.69, 0.52-0.91), ischemic stroke (0.68, 0.49-0.94), and hypoglycemia (0.23, 0.08-0.71), after accounting for major confounding factors. Conclusions: In T2D treatment, use of acarbose as the add-on remedy to metformin was associated with lower risks of major atherosclerotic events, ischemic stroke, and hypoglycemia, compared with sulfonylurea. |
| Date: | 2018-10 |
| Relation: | Journal of Clinical Endocrinology and Metabolism. 2018 Oct;103(10):3611-3619. |
| Link to: | http://dx.doi.org/10.1210/jc.2018-00040 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0021-972X&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000448258100005 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85054459941 |
| Appears in Collections: | [許志成] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB30113697.pdf | | 1014Kb | Adobe PDF | 322 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
